Volume 44, Issue 5 pp. 892-899
ORIGINAL ARTICLE

Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype

Nan Xu

Nan Xu

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Search for more papers by this author
Yue-Yun Lai

Yue-Yun Lai

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Search for more papers by this author
Wen-Min Chen

Wen-Min Chen

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Search for more papers by this author
Hao Jiang

Hao Jiang

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Search for more papers by this author
Yu Wang

Yu Wang

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Search for more papers by this author
Xu Wang

Xu Wang

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Search for more papers by this author
Xiao-Su Zhao

Xiao-Su Zhao

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Search for more papers by this author
Xiao-Jun Huang

Xiao-Jun Huang

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Search for more papers by this author
Qian Jiang

Corresponding Author

Qian Jiang

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Correspondence

Ya-Zhen Qin and Qian Jiang, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.

Email: [email protected] and [email protected]

Search for more papers by this author
Ya-Zhen Qin

Corresponding Author

Ya-Zhen Qin

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Correspondence

Ya-Zhen Qin and Qian Jiang, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.

Email: [email protected] and [email protected]

Search for more papers by this author
First published: 03 May 2022
Citations: 3

Abstract

Introduction

Adult acute myeloid leukaemia (AML) patients with complex karyotype (CK) generally have unfavourable outcomes. CK commonly co-exists with characteristic chromosomal and genetic abnormalities such as monosomal karyotype (MK), −17 or 17p- [abn(17p)] and TP53 mutations. Their individual prognostic significance needs to be clarified.

Methods

Seventy-three adult CK-AML patients and eleven adult non-CK-AML patients with TP53 mutations (non-CK/TP53mu) who were diagnosed and received therapy at our institute were enrolled. One hundred and fifty-seven AML cases retrieved from the cancer genome atlas (TCGA) for validation.

Results

Among CK-AML patients, those with TP53 mutations (CK/TP53mu) had significantly lower rates of 1-course induction complete remission (CR), 2-year relapse-free survival (RFS) and 2-year overall survival (OS) than those without TP53 mutations (CK/TP53wt); whereas, abn(17p) did not have the above impacts; MK was significantly associated with a lower 2-year OS rate but was not related to the rates of CR and RFS. Multivariate analysis showed that it were TP53 mutations and treating with chemotherapy alone but not MK and abn(17p) that independently predicted the adverse prognosis for RFS and OS in CK-AML. Furthermore, non-CK/TP53mu patients showed similar rates of CR, RFS and OS to CK/TP53mu patients. Validation using the TCGA cohort showed that CK/TP53mu patients had a significantly lower 2-year OS rate than CK/TP53wt patients, whereas abn(17p) and MK did not impact OS; the 2-year OS rate of patients with CK/TP53wt was similar to that of patients with intermediate-risk cytogenetics.

Conclusion

Adult CK-AML patients have varied risks and TP53 mutations seem to be an independent adverse prognostic factor.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.